Christine Sadlowski and Dr. Michael Williams talk to Dr. Alex Herrera about second interim results of a study that show promise for using the PD-1 inhibitor nivolumab instead of brentuximab vedotin for advanced-stage, classic Hodgkin's lymphoma.